Alto Neuroscience, Inc.

For the period ended Dec 31, 2024. Filed Mar 20, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 20, 2025

ANRO$27.80+10.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except per share amounts)

	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$168,229	$82,548
Prepaid expenses and other current assets	1,108	2,843
Total current assets	169,337	85,391
Restricted cash	500	—
Property and equipment, net	2,666	1,106
Operating right-of-use asset	5,035	—
Other assets	4	131
Total assets	$177,542	$86,628
Liabilities, convertible preferred stock and stockholders’ equity (deficit)
Current liabilities:
Accounts payable	$1,579	$1,074
Accrued expenses and other current liabilities	8,429	4,536
Total current liabilities	10,008	5,610
Term loan, non-current	10,254	9,861
Convertible Grant Agreement	1,304	—
Preferred stock warrant liability	—	1,352
Lease liability, long-term	4,516	—
Total liabilities	26,082	16,823
Commitments and contingencies (Note 15)
Convertible preferred stock	—	141,477
Stockholders’ equity (deficit):
Common stock (par value $0.0001), 500,000 and 52,000 shares authorized; 26,987 and 3,832 shares issued and outstanding as of December 31, 2024 and 2023	3	—
Additional paid-in capital	289,954	5,372
Accumulated deficit	(138,396)	(76,965)
Accumulated other comprehensive loss	(101)	(79)
Total stockholders’ equity (deficit)	151,460	(71,672)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$177,542	$86,628

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.